ArticleBiomedicines2025
Effects of Statins on All-Cause Mortality in Patients with Breast Cancer: A Population-Based Study.
Article in Biomedicines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The impact of statin therapy on the prognosis of hormone receptor-positive breast cancer: a systematic review and meta-analysis.Frontiers in oncology · 2026Pooled it
- Targeting cancer stem-like cells via cholesterol modulation and ferroptosis induction using a multifunctional nanoplatform to overcome drug resistance.Journal of nanobiotechnology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
This retrospective cohort study investigated the effects of statin use on 5-year clinical outcomes, particularly all-cause mortality, in patients with breast cancer. Clinical data of 971,808 patients who received a diagnosis of breast cancer between 2010 and 2020 were collected from the TriNetX platform. Eligible patients were classified as statin users (98,761) or nonusers (691,644). Statin use was defined by a prescription of statins being given within 3 years after breast cancer diagnosis. All-cause mortality and cardiovascular incidence were evaluated from Aalen-Johansen cumulative incidence curves. After 1:1 propensity score matching, all-cause mortality outcomes were analyzed in terms of hazard ratios and risk ratios. Our studies revealed that the risk of all-cause mortality was lower in statin users than in nonusers (hazard ratio: 0.798; risk ratio: 0.721;
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.